total cholesterol, LDL-cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, glucose, insulin, hemoglobin A1c and creatinine were measured. Serum Lp(a) was measured by turbidimetric immunoassay system (BML, Tokyo, Japan). The estimated glomerular filtration rate was calculated using the Japanese equation for estimating glomerular filtration rate from serum creatinine, and chronic kidney disease (CKD) was considered to be present if it was <60 ml · min -1 · 1.73 m −2 . Multivessel disease (MVD) was defined as ≥75% stenosis in 1 or more vessels remote from the infarcted artery. Informed consent was given by each patient and the study was approved by the ethical committee at Hiroshima City Hospital. Patients were classified into 2 groups based on Lp(a) level: high Lp(a) group (>40 mg/dl: n=95) and low Lp(a) group (≤40 mg/dl: n=315). Because a serum Lp(a) level of 40 mg/dl was the 75 th percentile of this population and 40 mg/dl was the normal upper limit in this assay, we defined patients with a serum Lp(a) level >40 mg/dl as the high Lp(a) group. Clinical follow-up was obtained up to 5 years. Follow-up angiography was encouraged at 6 and 12 months after primary PCI or earlier when clinically indicated. A major adverse cardiac event (MACE) was defined as cardiac death, MI and/or revascularization for new lesions. Revascularization for new lesions was defined as revascularization for >75% stenosis for non-target lesion that progressed more than 1 grade according to the classification of the American Heart Association. Cardiac death was defined as death from pump failure, sudden cardiac death or death because of arrhythmia. We also assessed the incidence of target lesion revascularization (TLR), but did not include it in MACE. 
Statistical Analysis
We used standard statistical methods. We tested the significance of difference with χ2 test for categorical variables. Student's t-test was used for continuous variables. Event-free survival curves up to 5 years after AMI were constructed with the Kaplan-Meier method and were compared with the log-rank test. Cox proportional hazard regression was used to identify independent predictors of mortality, adjusting baseline clinical and angiographic variables. We used the JMP statistical package (version 5.0.1 J) for all statistical tests. A significance level of 0.05 was used and 2-tailed tests were applied.
Results
The mean value of Lp(a) was 29.7±26.9 mg/dl, ranging from 1.0 to 190 mg/dl (Figure 1) . Baseline clinical and angiographic characteristics of the study patients are shown in Table 1 .
There was no significant difference in baseline variables between the high and low Lp(a) groups. Table 2 shows the laboratory data for the 2 groups. Patients with high Lp(a) had a significantly higher apoliprotein B level and apolipoprotein B/apolipoprotein A1 ratio than patients with low Lp(a). Figure 2a shows the 5-year cumulative incidence of MACE, which was significantly higher in patients with high Lp(a) than in those with low Lp(a) (34.7% vs. 16.5%, P<0.001). The incidence of each constituent factor of MACE at 5 years is shown in Table 3 . The difference in MACE was primarily driven by a higher incidence of revascularization for new lesion (Figure 2b) . Cardiac death, MI and revascularization for new lesions tended to be more frequent in patients with high Lp(a), but the differences did not reach statistical significance. There was no significant difference in the incidence of TLR (12.7% vs. 20.0%, P=0.10).
Multivariate analysis showed that Lp(a) was an independent predictor for MACE (odds ratio Tables 1,3 . Table 5 ). Other factors associated with 5-year revascularization for new lesion were MVD and CKD. If the utility of combining these 3 factors (high Lp(a), MVD and CKD), to predict revascularization for new lesions during the 5 years after AMI was assessed, there was a stepwise increase in revascularization for new lesions as the number of factors increased (Figure 3) .
Discussion
This study showed that high Lp(a) is an independent predictor of MACE after AMI in patients treated with primary PCI. It was primarily driven by the more frequent need of revascularization for new lesions in patients with high Lp(a). There are some mechanisms underlying the development of atherosclerosis. The pathophysiologic role of Lp(a) in atherosclerotic disease progression is explained by the accumulation of Lp(a) in the vessel wall and its ability to promote cholesterol accumulation in macrophages forming foam cells and subsequent fatty streaks 3,4 and to promote smooth muscle cell proliferation and migration in atherosclerotic lesions by inactivating transforming growth factor-β. 5 In contrast, the Lp(a) level was not associated with TLR. Since the introduction of coronary stents, the initial results of primary PCI have dramatically improved, 8, 9 The main cause of TLR is the growth of smooth muscle cells and fibroatheroma, which is thought to be strongly inhibited by the metallic scaffold of the stent. 10 However, this mechanism of TLR is different from that of non-TLR, so Lp(a) level was not associated with TLR. In addition, the procedure of primary PCI affects TLR. The use of drug-eluting stent (DES) further reduces TLR. Recently, the ACC/AHA guidelines updated their recommendations that it is reasonable to use DES as an alternative to bare metal stents for primary PCI in AMI patients. Despite the reduction in the MACE rate, however, DES does not improve survival. 11 It has been reported that, for the patients who survived AMI, long-term outcomes are determined mostly by events attributable to disease progression unrelated to the target lesion treated. Early risk stratification to predict disease progression of non-culprit lesions is, thus, important to improve the outcomes of patients with AMI. Previous studies have investigated the relation of Lp(a) to cardiovascular events. 12, 13 Recently, the Emerging Risk Factors Collaboration reported a meta-analysis of 126,634 participants in 36 prospective studies, 14 which showed that Lp(a) concentration was independently associated with the risk of coronary heart disease and stroke, but was unrelated to the aggregate of nonvascular mortality. The Lp(a) concentration was more consistent within individuals over several years than were levels of cholesterol, blood pressure, or other conventional risk factors. 15, 16 In the current study, we measured Lp(a) 1 week after AMI, and showed that a high Lp(a) concentration was associated with a higher incidence of revascularization for new lesions after AMI. The association was independent of conventional risk factors. Multivariate analysis showed that Lp(a), CKD and MVD, among the conventional risk factors, were independent predictors for MACE and revascularization for new lesions. Lp(a) is a biomarker that is genetically determined and consistent within individuals. On the other hand, CKD is frequently associated with progressive decline in the glomerular filtration rate, which leads to endstage renal disease and cardiovascular disease. CKD might enhance the activation of both the sympathetic nervous system and the renin -angiotensin -aldosterone system. 17 So, CKD is a marker that reflects increased levels of inflammatory and arterial sclerosis. In turn, MVD reflects atherosclerosis that is already present. Lp(a), CKD and MVD represent different markers of the development of new lesions, and the combination of Lp(a) with MVD and CKD was more useful for early risk stratification in patients with AMI who underwent primary PCI than each factor alone.
Prevention of atherothrombotic events of non-culprit lesions is important to reduce MACE after AMI in patients treated with primary PCI. Several studies have reported that the use of statins with a lower target LDL-cholesterol level slows atherosclerosis progression or reduces coronary plaque volume. [18] [19] [20] However, in this study, statins were prescribed in only onethird of the patients. Aggressive risk management may improve the outcomes of AMI patients with high Lp(a) concentrations. Although apolipoprotein-B100 is a component of Lp(a), contradictory findings have been reported about the effect of statins on the Lp(a) concentration. Importantly, available data are consistent with the existence of a causal relationship between high Lp(a) level and cardiac events, and increase the priority for investigating Lp(a) as a potential therapeutic target. Niacin can reduce the serum Lp(a) level. 21, 22 Recently, the Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies (ARBITE 6-HALTS) trial reported that niacin, when added to simvastatin for patients with low HDL level, decreased the carotid intima -media thickness. 23 However, the Lp(a) concentration was not measured and the increased HDL level may be attributable to the benefits obtained by niacin. Further studies are advocated to investigate better therapeutic options for patients with AMI and high Lp(a).
Study Limitations
This study suffers from the limitations of all retrospective studies. Small sample size is another limitation. In this study, 1 week after AMI, the samples were obtained because almost all patients were discharge within 10 days after AMI. However, it was been reported that most lipoprotein values decrease between 7 and 10 days after the onset of AMI. 24 By contrast, Slunga et al, in a study of 32 AMI patients, found no clear evidence of Lp(a) elevation in the acute phase. 25 Other reports suggest that the Lp(a) concentration reaches a peak on the 5 th day and then returns to the initial value within 1 week. 26 Further investigations are necessary to determine the transient increase in serum Lp(a) concentration after AMI.
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